Evidências científicas sobre o manejo do adenocarcinoma retal / Scientific evidence on the management of rectal adenocarcinoma

Karinne Nancy Sena Rocha, Letícia Hermont Azevedo, Michelle Paz De Araujo, Weslley Rodrigues Oliveira, Camila Bicalho Murta, Laís Soares Marques, Ana Beatriz Carvalho Drumond, Nadábia Ferreira Alves, Daniel Zanini Bernardino De Souza

Abstract


A ressecção cirúrgica é a base da terapia curativa para o adenocarcinoma retal, a cirurgia por si só fornece uma alta taxa de cura apenas para pacientes em estágio inicial da doença, a adição de quimioterapia e radioterapia antes e depois da cirurgia parece melhorar o prognóstico da doença. A radioterapia emergiu como um componente importante da terapia adjuvante para câncer retal por causa dos padrões distintos de falha após a ressecção.  A terapia neoadjuvante em vez de adjuvante, quimiorradioterapia de longa duração ou RT de curta duração sozinha, é uma abordagem preferida para pacientes com transmural ou tumores com nódulo-positivo, principalmente se estiverem baixos no reto e para aqueles com fáscia mesorretal positiva ou ameaçada. As vantagens da abordagem neoadjuvante incluem melhor controle local, uma maior probabilidade de cirurgia para salvar o esfíncter, um menor risco de disfunção intestinal pós-tratamento e um menor risco de estenose anastomótica.


Keywords


Adenocarcinoma, Quimioterapia Adjuvante, Terapia Neoadjuvante.

References


Minsky BD, Mies C, Recht A, et al. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer 1988; 61:1408.

Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv22.

Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52:1317.

Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291.

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology.

Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.

Reimers MS, Kuppen PJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. J Natl Cancer Inst 2014; 106.

Das P. Rectal cancer: do protons have prospects? J Gastrointest Oncol 2014; 5:1.

Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985; 312:1465.

Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324:709.

NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264:1444.

O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331:502.

Tepper JE, O'Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997; 15:2030.

Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol 2002; 20:1744.

Gieschke R, Burger HU, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 2003; 55:252.

Kalofonos HP, Bamias A, Koutras A, et al. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer 2008; 44:1693.

Kim TW, Lee JH, Lee JH, et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys 2011; 81:1025.

Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731.

Akasu T, Moriya Y, Ohashi Y, et al. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36:237.

Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004; 22:1785.




DOI: https://doi.org/10.34119/bjhrv5n1-033

Refbacks

  • There are currently no refbacks.